Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05367232 | A Study of ICP-033 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 60 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT04137900 | Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies | unknown | Phase 1 | 499 | TopAlliance BiosciencesINDUSTRY | 1 | Feb 5, 2024 |
| clinicaltrials |
| NCT06240767 | Clinical Study on the Treatment of Advanced Recurrent Tumors With Anticancer Mouse Characteristic Human Neutrophils | unknown | Phase 1 | 18 | Wuxi People's HospitalOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT05291182 | A Phase I Study of SY-4835 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 40 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT05743504 | Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients | unknown | Phase 1 / Phase 2 | 32 | National Taiwan University HospitalOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT05787535 | HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor | unknown | Phase 1 | 17 | HRYZ Biotech Co.INDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06037317 | A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors | unknown | Phase 1 | 38 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06232863 | A Study of BH009 in Head and Neck Squamous Cell Carcinoma and Ovarian Cancer | unknown | Phase 1 | 24 | Zhuhai Beihai Biotech Co., LtdINDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06239623 | ERK Inhibitor JSI-1187 in Advanced Solid Tumors | unknown | Phase 1 | 60 | JS InnoPharm, LLCINDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT04358393 | A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS | unknown | Phase 1 / Phase 2 | 69 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT04961632 | Dose-determining and Dose-confirmatory Study to Investigate the Optimal Dose of Tamoxifen in Breast Cancer Patients According to Genotype Status of TCF20 rs932376 | unknown | Phase 1 | 75 | National Cancer Centre, SingaporeOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT05573373 | Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer | unknown | Phase 1 | 40 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT05675605 | A Study of TY-1091 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 248 | TYK Medicines, IncINDUSTRY | 1 | Jan 30, 2024 | clinicaltrials |
| NCT03068624 | Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma | unknown | Phase 1 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT04983810 | A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma | unknown | Phase 1 / Phase 2 | 330 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 3 | Jan 25, 2024 | clinicaltrials |
| NCT06223308 | A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 54 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 25, 2024 | clinicaltrials |
| NCT06223646 | A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 29 | Novatim Immune Therapeutics (Zhejiang) Co., Ltd.INDUSTRY | 1 | Jan 25, 2024 | clinicaltrials |
| NCT06224842 | Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL | unknown | Phase 1 / Phase 2 | 30 | Huijing WuOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT06221774 | Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors | unknown | Phase 1 / Phase 2 | 42 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT04595994 | Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma(SeliSarc) | unknown | Phase 1 | 14 | Grupo Espanol de Investigacion en SarcomasOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05150405 | A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors | unknown | Phase 1 | 54 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05186012 | APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma | unknown | Phase 1 / Phase 2 | 51 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05576961 | Safety and Efficacy of RX-af01 Combined With PD-1 Antibody | unknown | Phase 1 / Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06010901 | A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer. | unknown | Phase 1 | 75 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06218771 | A Study of TQB3454 Tablets in Patients With Blood Tumors | unknown | Phase 1 / Phase 2 | 80 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05464173 | Chidamide in Combination With Abemaciclib and Endocrinotherapy（Doctor's Choice） in Breast Cancer Patients Previously Treated With Palbociclib(CINDERELLA) | unknown | Phase 1 / Phase 2 | 44 | Biyun Wang, MDOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT04224480 | Longitudinal Immune-phenotyping of HCC Following MK-3475 | unknown | Phase 1 | 8 | National Cancer Centre, SingaporeOTHER | 1 | Jan 19, 2024 | clinicaltrials |
| NCT06209671 | INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia | unknown | Phase 1 | 12 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 0 | Jan 17, 2024 | clinicaltrials |
| NCT04284228 | Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT | unknown | Phase 1 / Phase 2 | 22 | NexImmune Inc.INDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT05388487 | Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors | unknown | Phase 1 | 54 | HighField Biopharmaceuticals CorporationINDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT06200363 | A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer | unknown | Phase 1 | 15 | West China HospitalOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT06187740 | Thoracic Consolidation Radiotherapy for ES-SCLC Treated With Chemo-immunotherapy | unknown | Phase 1 | 28 | Fudan UniversityOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05522738 | Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 46 | Chinese PLA General HospitalOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT04720768 | Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE(CELEBRATE) | unknown | Phase 1 / Phase 2 | 78 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT05185531 | A Study of Neoadjuvant Tislelizumab With SBRT in Patients With Resectable Hepatocellular Carcinoma(Notable-HCC) | unknown | Phase 1 | 20 | Shandong Cancer Hospital and InstituteOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT05420493 | Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma | unknown | Phase 1 | 54 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jan 5, 2024 | clinicaltrials |
| NCT06144385 | A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma | unknown | Phase 1 | 20 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 2, 2024 | clinicaltrials |
| NCT06186440 | Cisplatin Plus Temozolomide Compared With Temozolomide in Patients With MGMT Promotor Unmethylated Glioblastoma(Glioblastoma) | unknown | Phase 1 / Phase 2 | 60 | Zhongnan HospitalOTHER | 0 | Jan 2, 2024 | clinicaltrials |
| NCT03807102 | Trial of Tumor Vaccine Used for Adjuvant Therapy in Post Radical Operation Patients With Lung Cancer(TVATLC01) | unknown | Phase 1 / Phase 2 | 30 | Yongchang ZhangOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT04714827 | Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 24 | Shanxi Province Cancer HospitalOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT04715217 | Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma | unknown | Phase 1 / Phase 2 | 24 | Shanxi Province Cancer HospitalOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT05164458 | Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies | unknown | Phase 1 | 320 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Dec 28, 2023 | clinicaltrials |
| NCT06104553 | A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma | unknown | Phase 1 / Phase 2 | 132 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 27, 2023 | clinicaltrials |
| NCT06182735 | CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma | unknown | Phase 1 | 9 | Fudan UniversityOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT04987112 | Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors | unknown | Phase 1 | 36 | CanWell Pharma Inc.INDUSTRY | 1 | Dec 22, 2023 | clinicaltrials |
| NCT04324294 | Contrast Enhanced Endoscopic Ultrasound in Pancreas Lesions | unknown | Phase 1 | 200 | Cedars-Sinai Medical CenterOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT05031949 | Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma(CCGLC-003) | unknown | Phase 1 | 20 | Zhang Bi Xiang, MDOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05533892 | Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC(CCGLC-007) | unknown | Phase 1 | 30 | Wan-Guang ZhangOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT06172634 | A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCs(CellgramDC-WT1) and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First-line or More Standard Chemotherapy(DICI_PC) | unknown | Phase 1 / Phase 2 | 10 | Soonchunhyang University HospitalOTHER | 0 | Dec 15, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Feb 7, 2024source: clinicaltrials